Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Teva’s Q2 2026 financial results for the quarter ended June 30, 2026 announced July 29, 2026.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Teva’s Q2 2026 financial results for the quarter ended June 30, 2026 announced July 29, 2026
- Detailed results, outlook and operating metrics contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $4.142B, down 1% YoY, as 15% LC generics decline offset 43% LC growth in key innovative brands
- AUSTEDO $696M, AJOVY $244M, and UZEDY $77M drove over $1B in combined quarterly revenue
- 2026 outlook raised for all three innovative brands, combined revenue target approximately $3.7B, roughly 17% YoY growth
- Emalex acquisition and ecopipam generated $726M of Q2 expenses, driving $0.49 GAAP loss per share and sharply lower operating profit
- 2026 guidance maintained: revenue $16.5B-$16.85B, free cash flow $2.0B-$2.4B, non-GAAP EPS $1.91-$2.11 including $0.66 per-share Emalex impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.